Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 31% during trading on Thursday . The company traded as high as C$0.23 and last traded at C$0.19. 457,687 shares traded hands during trading, a decline of 13% from the average session volume of 525,007 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The stock has a market cap of C$28.42 million, a price-to-earnings ratio of -5.69 and a beta of 0.20. The firm’s 50-day moving average is C$0.20 and its two-hundred day moving average is C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- 3 Monster Growth Stocks to Buy Now
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- 5 Top Rated Dividend Stocks to Consider
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What Are Dividend Achievers? An Introduction
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
